Glenmark Pharmaceuticals Limited EBIT

The latest EBIT for GLENMARK.NS is $27B as of June 2026. That compares with $15B in the prior-year period — up 80.1% year over year. That is above the sector sector average of $-25M. Investors often review this figure alongside Glenmark Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLENMARK.NS's EBIT moved from $15B to $27B — a 80.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Glenmark Pharmaceuticals Limited's operating scale or balance-sheet position.

Against its sector companies, GLENMARK.NS currently prints $27B for EBIT, while the sector average sits near $-25M. That is roughly 108118.3% above the sector mean. Large gaps often invite a closer look at Glenmark Pharmaceuticals Limited's growth, margins, and balance sheet.

A EBIT figure of $27B for GLENMARK.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-25M. Explore the charts below for those layers of context.

After noting GLENMARK.NS's EBIT ($27B), review year-over-year change from $15B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.